Tag Archives: pipeline

Deep Breadth: GSK Doubles Down on COPD and Asthma

Will GSK be able to maintain its position in COPD and asthma, post Advair/Seretide? Despite a patent expiry in 2010, generic versions of Advair aren’t expected to appear on the market for two more years. It took FDA eight years to develop a blueprint for how generics manufacturers might establish an acceptable bioequivalence for Advair, […]
Posted in Advertising, compliance, Emerging Markets, Europe, FDA, Global, Legal, R&D, Regulatory, Sales, Strategy | Also tagged , , , , , , , | Leave a comment

Drug Pipelines in Canada: Is There a Buyer for Future Innovation?

Last week, Canada’s National Prescription Drug Utilization Information System (NPDUIS), a federal-provincial fact-finding panel that works closely with the Patented Medicines Prices Review Board (PMPRB), issued its fourth New Drug Pipeline Monitor (NDPM) looking at drugs currently under development that may have an impact on future drug expenditures. The report is another example of how […]
Posted in Global, healthcare, IP, Market Access, Orphan Drugs, pricing, R&D, Regulatory | Also tagged , , , , | Leave a comment

Will "Robust Pipeline" Yield More New Drugs?

Biopharmaceutical companies are touting their huge investment in R&D, which has filled the drug pipeline with more potential first-in-class medicines, including orphan drugs, personalized medicines and new therapies based on novel scientific strategies. A report by the Analysis Group for the Pharmaceutical Research and Manufacturers of America (PhRMA) documents more than 5,000 new medicines in […]
Posted in Biotech, FDA, leadership, R&D, Regulatory | Also tagged , , , , , | Leave a comment

Pipeline Report Preview

Posted in Advertising, Biotech, Europe, FDA, Gene therapy, Global, IP, R&D, Regulatory, Strategy, Video | Also tagged , , , , , , , , | Leave a comment

Public Interest in Private Science: New Pathways to Measuring R&D Success

Today’s big product story — the apparent end to a decade-long drought in the drug development pipeline — is the prep stage for tomorrow’s big policy question:  are industry R&D priorities in synch with the changing burden of disease?
Posted in FDA, R&D | Also tagged , , | Leave a comment
  • Categories

  • Meta